Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada.
Age distribution
COVID-19
Epidemiology
Hospitalization
Infectious disease
SARS-CoV-2
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
received:
30
11
2020
accepted:
08
03
2021
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Patient age is one of the most salient clinical indicators of risk from COVID-19. Age-specific distributions of known SARS-CoV-2 infections and COVID-19-related deaths are available for many regions. Less attention has been given to the age distributions of serious medical interventions administered to COVID-19 patients, which could reveal sources of potential pressure on the healthcare system should SARS-CoV-2 prevalence increase, and could inform mass vaccination strategies. The aim of this study is to quantify the relationship between COVID-19 patient age and serious outcomes of the disease, beyond fatalities alone. We analysed 277,555 known SARS-CoV-2 infection records for Ontario, Canada, from 23 January 2020 to 16 February 2021 and estimated the age distributions of hospitalizations, Intensive Care Unit admissions, intubations, and ventilations. We quantified the probability of hospitalization given known SARS-CoV-2 infection, and of survival given COVID-19-related hospitalization. The distribution of hospitalizations peaks with a wide plateau covering ages 60-90, whereas deaths are concentrated in ages 80+. The estimated probability of hospitalization given known infection reaches a maximum of 27.8% at age 80 (95% CI 26.0%-29.7%). The probability of survival given hospitalization is nearly 100% for adults younger than 40, but declines substantially after this age; for example, a hospitalized 54-year-old patient has a 91.7% chance of surviving COVID-19 (95% CI 88.3%-94.4%). Our study demonstrates a significant need for hospitalization in middle-aged individuals and young seniors. This need is not captured by the distribution of deaths, which is heavily concentrated in very old ages. The probability of survival given hospitalization for COVID-19 is lower than is generally perceived for patients over 40. If acute care capacity is exceeded due to an increase in COVID-19 prevalence, the distribution of deaths could expand toward younger ages. These results suggest that vaccine programs should aim to prevent infection not only in old seniors, but also in young seniors and middle-aged individuals, to protect them from serious illness and to limit stress on the healthcare system.
Sections du résumé
BACKGROUND
Patient age is one of the most salient clinical indicators of risk from COVID-19. Age-specific distributions of known SARS-CoV-2 infections and COVID-19-related deaths are available for many regions. Less attention has been given to the age distributions of serious medical interventions administered to COVID-19 patients, which could reveal sources of potential pressure on the healthcare system should SARS-CoV-2 prevalence increase, and could inform mass vaccination strategies. The aim of this study is to quantify the relationship between COVID-19 patient age and serious outcomes of the disease, beyond fatalities alone.
METHODS
We analysed 277,555 known SARS-CoV-2 infection records for Ontario, Canada, from 23 January 2020 to 16 February 2021 and estimated the age distributions of hospitalizations, Intensive Care Unit admissions, intubations, and ventilations. We quantified the probability of hospitalization given known SARS-CoV-2 infection, and of survival given COVID-19-related hospitalization.
RESULTS
The distribution of hospitalizations peaks with a wide plateau covering ages 60-90, whereas deaths are concentrated in ages 80+. The estimated probability of hospitalization given known infection reaches a maximum of 27.8% at age 80 (95% CI 26.0%-29.7%). The probability of survival given hospitalization is nearly 100% for adults younger than 40, but declines substantially after this age; for example, a hospitalized 54-year-old patient has a 91.7% chance of surviving COVID-19 (95% CI 88.3%-94.4%).
CONCLUSIONS
Our study demonstrates a significant need for hospitalization in middle-aged individuals and young seniors. This need is not captured by the distribution of deaths, which is heavily concentrated in very old ages. The probability of survival given hospitalization for COVID-19 is lower than is generally perceived for patients over 40. If acute care capacity is exceeded due to an increase in COVID-19 prevalence, the distribution of deaths could expand toward younger ages. These results suggest that vaccine programs should aim to prevent infection not only in old seniors, but also in young seniors and middle-aged individuals, to protect them from serious illness and to limit stress on the healthcare system.
Identifiants
pubmed: 33845807
doi: 10.1186/s12889-021-10611-4
pii: 10.1186/s12889-021-10611-4
pmc: PMC8040357
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
706Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
PLoS Med. 2007 May;4(5):e174
pubmed: 17518515
JAMA Netw Open. 2020 Jul 1;3(7):e2015957
pubmed: 32697325
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Aging (Albany NY). 2020 Jun 4;12(11):10070-10086
pubmed: 32499448
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Travel Med Infect Dis. 2020 Sep - Oct;37:101651
pubmed: 32247928
Lancet. 2021 Feb 6;397(10273):455-457
pubmed: 33357467
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Lancet Public Health. 2020 Nov;5(11):e612-e623
pubmed: 33065023
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371
J Clin Virol. 2020 Jun;127:104379
pubmed: 32361325
JAMA Intern Med. 2020 Sep 1;180(9):1163-1164
pubmed: 32356871
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2020 Aug 20;383(8):e56
pubmed: 32767891
Sci Adv. 2021 Feb 3;7(6):
pubmed: 33536223
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797